{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=38&state=Ohio", "query": { "state": "Ohio", "city": "Columbus", "page": 38 }, "page_size": 10 }, "pagination": { "page": 38, "page_size": 10, "total_count": 10863, "total_pages": 1087, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=39&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=37&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T07:33:38.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02266914", "title": "Magnetic Resonance Elastography of Cardiac Transplant Rejection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Graft Rejection" ], "interventions": [ { "name": "Magnetic Resonance Elastography driver", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-01-27", "completion_date": "2017-12-01", "has_results": true, "last_update_posted_date": "2019-05-22", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02266914" }, { "nct_id": "NCT02586233", "title": "Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Ischemic Stroke", "Thrombotic Disease" ], "interventions": [ { "name": "DS-1040b", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2015-09", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 16, "location_summary": "Mobile, Alabama • Los Angeles, California • Colorado Springs, Colorado + 13 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02586233" }, { "nct_id": "NCT03358147", "title": "Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "GP MDI 28.8 μg", "type": "DRUG" }, { "name": "GP MDI 14.4 μg", "type": "DRUG" }, { "name": "GP MDI 7.2 μg", "type": "DRUG" }, { "name": "Placebo MDI", "type": "DRUG" }, { "name": "Spiriva Respimat 2.5 μg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "12 Years to 80 Years" }, "enrollment_count": 1077, "start_date": "2017-12-13", "completion_date": "2019-09-12", "has_results": true, "last_update_posted_date": "2020-08-12", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 232, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 188 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03358147" }, { "nct_id": "NCT01578655", "title": "Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "cabazitaxel", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "custirsen sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Achieve Life Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 630, "start_date": "2012-08", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-12", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 35, "location_summary": "Marina del Rey, California • Sacramento, California • San Diego, California + 32 more", "locations": [ { "city": "Marina del Rey", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578655" }, { "nct_id": "NCT03328936", "title": "Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic Cell Transplantation Recipient", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-09-01", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2020-02-21", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03328936" }, { "nct_id": "NCT04964934", "title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ER-Positive HER2-Negative Breast Cancer" ], "interventions": [ { "name": "AZD9833", "type": "DRUG" }, { "name": "AZD9833 Placebo", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Anastrozole placebo", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Letrozole placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Luteinizing hormone-releasing hormone (LHRH) agonist", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 315, "start_date": "2021-06-30", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 64, "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04964934" }, { "nct_id": "NCT04711109", "title": "Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "BRCA1 Mutation", "Breast Cancer", "Breast Diseases", "Breast Neoplasms", "Breast Carcinoma", "Neoplasms" ], "interventions": [ { "name": "Denosumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "25 Years to 55 Years · Female only" }, "enrollment_count": 300, "start_date": "2023-02-14", "completion_date": "2033-12", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 47, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04711109" }, { "nct_id": "NCT07582432", "title": "A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Gamunex-C, 10% Injectable Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Biologicals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2026-05-11", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 5, "location_summary": "St. Petersburg, Florida • Fort Wayne, Indiana • Westbrook, Maine + 2 more", "locations": [ { "city": "St. Petersburg", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Westbrook", "state": "Maine" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07582432" }, { "nct_id": "NCT03488693", "title": "Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Radiation", "type": "RADIATION" }, { "name": "No Radiation", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Canadian Cancer Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "FEMALE", "summary": "35 Years and older · Female only" }, "enrollment_count": 2138, "start_date": "2018-10-16", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 451, "location_summary": "Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03488693" }, { "nct_id": "NCT00877006", "title": "Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "bendamustine", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2009-04-30", "completion_date": "2012-03-31", "has_results": true, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-11-15T07:33:38.214Z", "location_count": 79, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877006" } ] }